SOPHiA GENETICS Q3 revenue rises on US market strength 

Overview

• Switzerland-based AI precision medicine firm's Q3 revenue rose 25% yr/yr

• Company's adjusted EBITDA loss narrowed 31% yr/yr

• Company expects 2026 revenue at upper end of guidance, but warns on FX headwind for Q4

Outlook

• Company expects 2026 revenue at upper end of $94 mln to $96 mln range

• Company sees 2026 adjusted EBITDA loss between $29 mln and $32 mln

• Company says foreign exchange rates could weigh on Q4 revenue if trends persist

Result Drivers

• ANALYSIS VOLUME & BIOPHARMA - Co said record analysis volume, strong U.S. market performance, and BioPharma momentum drove Q3 revenue growth, per CEO Ross Muken

• VOLUME GROWTH - Record 118,000 analyses performed in Q3, up 19% yr/yr

• U.S. MARKET - Q3 U.S. revenue rose 41% yr/yr, helping drive overall results

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Reuters Recommended Reads

• Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

• Nov 3 - Netherlands' Philips slightly misses Q3 revenue estimates, maintains 2026 forecast

• Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)